The Use of Prosthetic Stents in Tracheobronchial,
Gastrointestinal, and Genitourinary Diseases by Edell, Eric S. et al.
Diagnostic and Therapeutic Endoscopy, Vol. 1, pp. 1-8
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1994 Harwood Academic Publishers GmbH
Printed in Malaysia
The Use of Prosthetic Stents in Tracheobronchial,
Gastrointestinal, and Genitourinary Diseases
ERIC S. EDELL*, ROLLIN W. HUGHES, JR.’,
JOSEPH E. OESTERLING and DENIS A. CORTESE**
*Division ofThoracic Diseases, Mayo Clinic, Rochester, MN
**Division ofThoracic Diseases, Mayo Clinic, Jacksonville, FL
fDivision ofGastroenterology, Mayo Clinic, Rochester, MN
CfDepartment of Urology, Mayo Clinic, Rochester, MN
(Received infinalform January 24, 1994)
The concept of using a stent to maintain patency of a lumen is not new. As early as 1969, stents were
being investigated in the peripheral medal system as a means of preventing restenosis after dilata-
tion by balloon angioplasty (Dotter, 1969). Since then, numerous reports have demonstrated the use
of stents in both the peripheral and coronary artery systems (Maass et al., 1982; Dotter et al., 1983;
Wright et al., 1985; Palmaz et al., 1987). Concomitant with the investigation of expandable en-
dovascular metal prosthesis has been the development of prosthetic devices for management of tra-
cheobronchial, gastrointestinal, and genitourinary diseases.We will review the use ofendoscopically
placed prosthetic devices in the management of diseases affecting these systems.
KEY WORDS: tracheobronchial stents, gastrointestinal stents, genitourinary stents, bronchial
stricture, prostatic hypertrophy, biliary tract
ENDOSCOPIC PLACEMENT OF PROSTHETIC
DEVICES IN GENITOURINARY TRACT
Fabian (Fabian, 1980) was the first to describe the use of
a stent or spiral in the lower urinary tract. He placed a
metallic endoprosthesis in the prosthetic urethra of poor
surgical risk patients in urinary retention as a result of an
enlarged prostate. Based upon these results and the suc-
cessful outcome of others, itbecame clear that stenting of
the lower urinary tract was a workable concept (Fabricius
et al., 1983; Flier and Seppelt, 1987).
At the present time, there are a number of intraurethral
endoprostheses being developed for use in the lower uri-
nary tract. However, the two permanently implanted in-
traurethral stents that have been investigated most
extensively in both Europe and the United States are the
Intraprostatic Stent by advance surgical intervention (San
Clemente, California), and the UroLume Endoprosthesis,
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which is being marketed by American Medical Systems
(Minnetonka, Minnesota). The Intraprostatic Stent has
been evaluated primarily as a treatment of bladder outlet
obstruction secondary to an enlarged prostate gland.
However, the UroLume Endoprosthesis has been investi-
gated as a treatment option for three urologic conditions:
1) recurrent bulbar urethral strictures; 2) benign prostatic
hypertrophy; and 3) detrusser external sphincter duissyn-
ergia. In the discussion that follows, the data relating to
the role of the UroLume Endoprosthesis in the lower uri-
nary tract are reviewed.
Recurrent Bulbar Urethral Strictures
The initial experience with this permanently indwelling
endoprosthesis in the treatmentofrecurrentbulbarurethral
strictures comes from England. In 1988, Milroy and col-
leagues (Milroy et al., 1988) reported their preliminary re-
suits on eight patients. All of these men (mean age: 57
years; range: 33-78years)hadbeenpreviously treatedwith
a minimum of two direct vision internal urethrotomies
(DVIU) and multiple urethral dilatations without success2 E.S. EDELL et al.
and were awaiting a formal urethroplasty. After first dilat-
ing the dense stricture to 30-French (1.0cm), theUroLume
Endoprosthesis was placed across the stenosed area.
In two patients (25%), the endoprosthesis was inserted
under radiological control, and in six (75%), the stent was
positioned in the bulbar urethra under direct vision using
an optical telescope. With a mean followup of 8 months
(range: 6 months-1 year), no patient developed a recurrent
stricture. All men had total resolution of their obstructive
symptomsandanexcellentcaliberurethraonfollowupcys-
toscopic examination. For the seven patients with urody-
namic data available, the mean peak urinary flow rate
increased from 8.3 +/- 1.8 ml/second prestent placement to
22.6 +/- 7.0 ml/second postprocedure (p < 0.001). The only
side effect observed in this preliminary study was occa-
sional post-micturation dribbling for several weeks after
stent placement. In the following year, these same investi-
gators presented a followup report on 12 patients (mean
age: 59 years; range: 31-88 years) with recurrent bulbar
urethral strictures who were treated with the UroLume
Endoprosthesis (Milroy et al., 1989). A total of 17 stents
were inserted; 9 patients (75%) receivedone stent, oneman
(8%) had two stents, and 2 individuals (17%) had three
stents inserted tocompletelycoverthe stdctured area. With
the followup period ranging from 2 to 13 months (mean:
7 months), no stricture recurred. For the 11 evaluable pa-
tients, the mean peak urinary flow rate increasedby 200%
(7.6 +/- 2.3 ml/second pre-insertion to 22.8 +/- 8.4 ml/second
poststent placement). By 4 to 6 months after placement,
the stents were completely covered with urothelium, and
thus no longer exposed to the urine during micturation.
Untoward effects included transient, milddiscomfort atthe
stent site for 2 to 3 weeks in five men (42%); five other pa-
tients complained ofmild postvoid dribbling after stent in-
sertion. There was no evidence of encrustations or
infection, and no patient complained of alteration in ejac-
ulation or ability to achieve an erection.
Ashken and colleagues (Ashken et al., 1991) reported
theEuropeanexperiencewiththeUroLumeEndoprosthesis
as a treatment for difficult bulbar urethral strictures. With
four urologic centers participating, 71 patients (mean age:
56 years; range: 30-81 years) were managed with the en-
doprosthesis over a 3-year period. The most common eti-
ology was iatrogenic, and all patients had undergone
multipleprevioustreatments withoutsuccess. Allmenwere
followed for a minimum of 6 months, and 12 (17%) had
been monitored for over 2 years after stent placement.
Subjectively, 96% (68 patients) were pleased with the out-
come. Objectively, the mean peak urinary flow rate in-
creased from 6 ml/second pre-insertion to 20 ml/second in
3 months (p < 0.01), 18 ml/second at 8 months (p < 0.01),
and 22 ml/second at 15 months (p < 0.01) post-stem place-
ment. No patient developed a recurrent stricture. The au-
thors, however, commented that none ofthe patients in the
series had a traumatic stricture; they recommended that
traumatic strictures, which can be associated with very
dense fibrous tissue, should not be managed with the
UroLumeEndoprosthesis.As forthepresent series,theonly
notable untoward effects were urethral and perineal dis-
comfort and occasional postvoid dribbling in the immedi-
ate postoperative period. There was no difficulty with
infection or encrustations. The North American UroLume
Study Group also evaluated the UroLume Endoprosthesis
in a multicenter clinical trial (Oesterling et al., 1993). One
hundred and seventy-five patients (mean age: 52 years;
range: 17-90years) with recurrentbulbarurethral strictures
underwent treatment with the UroLume Endoprosthesis.
The mean number of previous treatments (urethral dilata-
tion or DVIU) per patient was 18. Stricture length for the
entire cohort varied from 0.4cm to 5.5 cm (mean: 2.2 cm).
The results at 12 months followup were most encouraging.
The total symptom score decreased from 12.7 +/- 5.1 pre-in-
sertion to 2.1 +/- 2.3 (p< 0.001). With voided volumes in ex-
cess of 150 cc, the peak urinary flow rate increased from
9.7 _
6.1 cc/second pre-insertion to 22.2 +/- 10.8 cc/second
(p < 0.001). At 6 months post-insertion, 74% of the endo-
prostheses were completely covered with epithelium (Fig.
4). As of this time, there has been no difficulty with infec-
tion, erosion, encrustations, migration, continence, or po-
tency. Several ofthe younger patients, however, have noted
perineal discomfort with nocturnal erections in the postop-
erative period. For all such patients, this untoward effect re-
solved within 6 to 8 weeks. Approximately 50% of the
patients did have a mild degree of postvoid dribbling.
Twenty-sixmen (15%) have required a second treatment to
manage the urethral stricture; sixteen patients underwent
placement of a second endoprosthesis, eight patients had
an endourethral resection, one patient was managed with
urethral dilatation, and one person had laser ablation ofthe
tissue regrowth. Six patients (3%) have undergone stent re-
moval; all prostheses were removed without difficulty and
subsequent sequelae. These preliminary results from both
Europe and the United States suggest that the flexible, self-
expanding intraurethral stentmay be an effective treatment
for recurrent bulbar urethral strictures. Investigations with
more patients and extended followup (years), however, will
be necessary to determine the true durability of the endo-
prosthesis and assess late complications.
Benign Prostatic Hyperplasia
As for bulbar urethral strictures, the early experience with
the UroLume Endoprosthesis in the treatment of BPH
comes from England, where this device has been utilizedTHE USE OF PROSTHETIC STENTS 3
sinceJanuary 1989 in patientswho are apoor surgical risk.
In a series of 12 patients described by Chapple and asso-
ciates, 11 (95%) were "fully satisfied" and able to urinate
without difficulty during a mean followup of 8.2 months
(range: 1-11 months) (Chapple et al., 1990). The one dis-
satisfied patient complained of significant frequency and
urgency; this phenomenon was found on subsequent uro-
dynamic evaluation to be associated with severe, persis-
tent detrusor instability. The mean peak urinary flow rate
at followup for the 12 patients, 9 ofwhom were in urinary
retention prior to stent placement, was 13.6 +/- 4.7 ml/sec-
ond. The postvoid residual urine volume after stent place-
ment was minimal. With respect to untoward effects, all
12 patients experienced some degree ofirdtative voidings
symptoms in the immediate postoperative period. These
symptoms subsided markedly within 4 to t5 weeks.
In a more recent report of 45 surgically unfit patients
treated with the UroLume Endoprosthesis, Milroy and
colleagues, indicated that 42 (93%) were pleased with the
outcome; all were "passing urine normally with suffi-
ciently reduced residual urine volumes" (Milroy, 1991).
Most patients, however, suffered urgency, frequency, and
occasional urge incontinence following stent placement;
these symptoms tended to resolve within several months,
as the endoprosthesis became covered with epithelium.
Most often, the stem becomes covered with urothelium
within 4 to 6 months’ time, which is somewhat faster than
that which occurs in the bulbar urethra. At 6 to 9 months
after stent placement, these investigators did notice a sig-
nificant amount of hyperplastic tissue growing through
the intertices of the wall of the stent. However, by 12 to
18 months post-stent insertion, this had subsided
markedly and was of no concern. No encmstations were
observed on any part ofthe endoprosthesis located within
the prostatic urethra. However, if the proximal end of the
stent is allowed to extend across the bladder neck into the
bladder, "fine encmstations" can develop on this aspect
ofthe device 6 to 12 months afterplacement. In the Milroy
series, it has been necessary to remove five stents. All de-
vices were removed without difficulty. Two were not po-
sitioned properly at the time of deployment and were
removed immediately, and a second stent was inserted;
two others were removed 4 weeks after placement, and
one was taken out 11 months after insertion. The tech-
nique for removing an endoprosthesis after it has become
covered with epithelium is as follows. Once the overlying
epithelium has been resected with a low-current resecto-
scope, the stent isjarred from it’s bed in the prostatic ure-
thra with a forceps. The stent is then grasped
approximately 0.5 cm from its distal edge and pulled gen-
tly; it will lengthen and decrease in diameter (much like
a Chinese finger toy) so that it can be pulled inside a re-
sectoscope sheet and removed without trauma to the ure-
thraorthe external urinary spinchter(Chapple and Milroy,
1989). McLoughlin and co-workers (McLoughlin et al.,
1990) described 19 major-risk patients, all ofwhom were
in urinary retention, who underwent placement of the en-
doprosthesis in the prostatic urethra with local anesthesia
only. All patients tolerated the procedure with minimal to
no discomfort, and all were able to "void spontaneously"
during the followup period (mean: 4 months; range: 3-7
months). Fifteen patients (79%) had severe urgency, fre-
quency, or discomfort with urination for 3 to 4 days after
stent placement. For most patients, this untoward effect
resolved within 8 weeks. All stents were noted to be cov-
ered with epithelium after 4 months. At the 1993 annual
meeting of the American Urological Association,
Oesterling (Oesteding 1993) reported the results of the
NorthAmerican Clinical Trial. Ninty-five healthy patients
(mean age: 68 +/- 7.5 years) with obstructive BPH elected
to be treated with the UroLume Endoprosthesis. Unlike
most patients being considered for treatment with the de-
vice in Europe, these men were sexually active and could
have readily undergone a transurethral resection of the
prostate gland. All patients were evaluated prior to stent
placementand in followup with a standardsymptomques-
tionnaire, peak urinary flow rate, postvoid residual urine
volume, and cystoscopic examination. The patients found
to have a large, median lobe or considered to have a hy-
potonic bladderwere excluded from participation. The re-
suits at 12 months followup were excellent. The total
symptom scored decreased from 15.0 +/- 5.5 pre-insertion
to 6.3 +/- 5.8 (p < 0.001). With voided volumes in excess
of 150 cc, the peak urinary flow rate increased from 8.6
+/- 3.5 cc/second pre-insertion to 15.6 +/- 6.2 cc/second (p
< 0.001). The postvoid residual urine volume decreased
from a 129 +/- 14.6 cc to 24 +/- 44 cc (p < 0.001). By 6
months, 55% ofthe endoprostheses were completely cov-
ered with epithelium; 45% still had some aspect of the
stent exposed at the bladder neck. There was no signifi-
cant difficulty with infection, erosion, migration, conti-
nence, orpotency;67% ofthe patients, however, hadsome
irritative symptoms (urgency, frequency, or dysuria) for
at least 1 month after stent placement. Nine stents have
been removed; all prostheses were removed without in-
jury to the external urinary sphincter or the urethra. These
results from both Europe and the United States are en-
couraging. Nevertheless, additional studies with extended
followup will be necessary to establish.the true, long-term
usefulness of this endoprosthesis in the management of
symptomatic BPH. A prospective, randomized clinical
trial, comparing the UroLume Endoprosthesis with
transurethral section of the prostate gland, is now under-
way in the United States and Canada.4 E.S. EDELL et al.
Detrusor External Sphincter Dyssynergia
Supraspinal cord injuries most often result in some degree
of detrusor external sphincter dyssynergia (Barkin et al.,
1983). The majority ofpatients develop significant detru-
sor-external sphincter dyssynergia and require theraputic
intervention. The two standard treatments are: 1) anti-
cholinergic therapy (to decrease uninhibited bladder con-
tractions and improve vesical compliance) with clean
intermittent catheterization, and 2) external striated
sphincterotomy to reduce bladder outlet resistance. The
former option is only a consideration ifthe patienthas suf-
ficient manual dexterity. The latter treatment, on the other
hand, does not always result in a favorable outcome. The
results of endoscopic external sphincterotomy have been
variable; overall, the success rate of this procedure is ap-
proximately 79 to 90%, as destruction of the entire exter-
nal urinary sphincter is not always technically easy
(Whitmore et al., 1978). Side effects, such as rectal dys-
function and hemorrhage, also can be significant. Thus,
there is much interest in developing a more simple, yet re-
liable, approach to achieving a functional external sphinc-
terotomy. To this end, the UroLume Endoprosthesis is
being investigated both abroad and in the United States as
an alternative treatment for detrusor-extemal sphincter
dyssynergia. In 1990, Shaw and colleagues (Shaw et al.,
1990) described nine patients with complete quadraple-
gia and detrusor-external sphincter dyssynergiawho were
managed with the UroLume Endoprosthesis instead of
sphincterotomy; followup ranged from 12 weeks to 10
months. In sixmen (67%), a3-cm endoprosthesis was suf-
ficient to completely traverse the external sphincter; three
patients (33%) required additional stents. Eight patients
(89%) had marked improvement in bladder emptying; the
mean postvoid residual urine volume decreased from 268
ml prestent insertion to 92 ml following the procedure.
The other patient did not achieve complete bladder emp-
tying and is awaiting urinary diversion. No complications
were encountered in this series. McInerney and associates
(McInemey et al., 1991) placed this endoprosthesis in 22
patients with neurological conditions resulting in signifi-
cant detrusor-external sphincter dyssynergia. Fourteen
(64%) of these men had undergone previous surgery on
the outflow tract; eleven had had repeated unsuccessful
external sphincterotomies,andthreehadundergoneplace-
ment ofan artificial urinary sphincter at the bladder neck.
With a maximum follow-up of 1 year, 15 (68%) achieved
complete voiding after the procedure; 3 (14%) developed
bladder neck obstruction after stenting the external uri-
nary sphincter. The endoprosthesis was ofno value in the
three patients who had an artificial urinary sphincter
placed previously at the bladder neck. Chancellor
(Chancellor et al., 1993) most recently reported the re-
suits of the North American Clinical Trial evaluating the
UroLume Endoprosthesis as a treatment for detrusor-ex-
ternal sphincter dyssynergia (Fig. 6A and 6B). One hun-
dred and nineteen spinal cord-injured men with this
condition, as verified by urodynamic evaluation, were
managed with an endoprosthesis and followed for 3 to 21
months. Thirty-two patients (27%) required two prosthe-
ses to completely bridge the external urinary sphincter.
Voiding pressures decreased from 77.7 + 26.2cm ofwater
before prosthesis placement, to 40.7 +_. 16.5 cm of water
at 3 months, 30.2 _
15.2 cm of water at six months, and
26.1 +_. 13.4cm ofwater at twelve months (p 0.001). The
postvoid residual urine volume decreased from 188.9 _.+
128.9 ml preoperatively to 112.5 __. 128.6 ml at 12-months
followup (p 0.008). Bladder capacity, however, re-
mained constant (p 0.3). All the patients with a pros-
thesis in proper position were able to achieve spontaneous
reflex voiding without constant dribbling. Encrustations,
infection, erosion, pain, and obstructive hyperplastic ep-
ithelial overgrowth did not occur in any patient. No deliri-
ous effects were seen with regard to renal or erectile
function. In five patients, however, it was necessary to re-
move the device because of stent migration. Based on
these preliminary results, it appears that the flexible, ep-
ithelizing UroLume Endoprosthesis may be an effective
treatment for select patients requiting an external sphinc-
terotomy. Nevertheless, it is only through long-term fol-
low-up ofmany patients that the real effectiveness of this
device will be demonstrated. Ideally, a prospective, ran-
domized clinical trial comparing the UroLume
Endoprosthesis with the goal of standard care, the endo-
scopic external sphincterotomy, should be conducted.
ENDOSCOPIC PLACEMENT OF PROSTHETIC
DEVICES IN GASTROENTEROLOGY
Endoscopic placement of prosthetic devices has been
shown to be effective in three areas of gastroenterology.
This includes obstruction from esophageal carcinoma,
malignant biliary tract obstruction, and obstruction of the
pancreatic ducts.
Esophageal Stenting
Adenocarcinoma of the esophagus continues to rise dra-
matically as a leading cause of cancer death worldwide.
The presentation of a patient with esophageal cancer is
frequently by symptoms due to obstruction. In planning
therapy, the level oftumor involvement is important. The
esophagus is divided into three segments. The upper,THE USE OF PROSTHETIC STENTS 5
which extends from the cdcopharyngeus to 23 cm from
the dentures, the middle level, which extends from 24 cm
to 32cm, andtheloweresophageal segment, which is from
33 cm to thejunction ofthe stomach. Tumors ofthe upper
and middle third are generally beyond surgical cure at the
time oftheir clinical presentation. It is has been estimated
that 15 to 20% of patients with advanced esophageal car-
cinomashouldbeconsideredforesophageal stenting. This
is particularly so after surgery, radiotherapy, chemother-
apy, and laser therapy have been utilized. The tubes that
have been used are constructed of polyvinyl plastic, latex
rubber, or silicone rubber. They may be reinforced by a
metal spiral, and have a proximal funnel construction
which facilitates endoscopic placement.
A self-expanding silicone-covered tube (Gianturco
stent) was used for palliation of esophago-respiratory fis-
tula related to esophageal cancer in eight patients by Do
(Do et al., 1993) at the Korea Cancer Center Hospital. All
fistula were successfully occluded by these expanding
tubes. The expanding tubes imbed themselves into the
esophageal wall, and a significant tissue hyperplasia oc-
curs, particularly at the edge of the tube.
Radiologists at the University Hospital, Lund, Sweden
have implanted nitinol self-expanding stents in40 patients
with dysphagia (Cwikiel et al., 1993). There were no im-
mediate complications, although ingrowth of the tumor
was seen in eight patients. Two of the patients had occlu-
sion of the stent by tumor and required laser resection to
re-establish luminal patency.
The Gianturco metallic stent was used by Iwasaki and
collegues (Iwasaki et al., 1993) to bridge amalignant stric-
ture of a esophagojejunostomy. Truong and collegues
(Truong et al., 1992) also reported palliative treatment of
malignant gastric outlet obstruction using a self-expand-
ing metal stent.
Biliary Duct and Pancreatic Duct Stenting
The placement of biliary and pancreatic endoprostheses is
also receiving intensive study and experimentation.
Endoscopic stent placement has become accepted pallia-
tion for patients with inoperable malignant biliary tract ob-
struction. Specific conditions that may be amenable to
stenting include pancreatic and biliary carcinoma, or
metastatic lesions that either compress or infiltrate the bil-
iary tree such as carcinoma of the gallbladder, carcinoma
of the stomach, or cancers arising in the colon, breast, etc.
The major condition that has benefitted from endoscopic
stenting hasbeenpancreatic adenocarcinoma. Ofthis group
ofpatients, 22 percent alsohad malignant hilar obstruction.
The success rate for endoscopic placement of biliary
stents is approximately 80 to 93% and the overall success
of insertion is judged by evaluating complications en-
countered in obtaining the goals of the procedure. A pre-
liminary goal in the treatment of malignant obstruction is
the relief ofjaundice. Kodakin and Starnes (Kodakin and
Starnes, 1992) have compared the 10 French and the 11.5
French polyethylene biliary stents, and their effectiveness
in obtaining relief of icterus, and decline of total biliru-
bin. They concluded that there is no significant advantage
between these stent sizes. However, the stent patency is
approximately twice as long for the 10 French polyethyl-
ene stent compared to the 7 French stent. There is a slight
tendency for a higher complication rate using the larger
stent (Pedersen, 1993).
The occlusion rate most certainly impacts on the ac-
ceptance of stenting of the biliary ductal system as pal-
liative therapy. The occlusion rate for a 10 French or 11.5
French stent at 3 months is 42%, and at 6 months is 10.8%
(Davids et al., 1992). Furthermore, a worse clinical re-
sponse and poorer survival is seen in the group ofpatients
who have undergone stenting for metastatic cancer
(Frakes et al., 1993).
The search for a better stent is primarily based on the
ease of insertion and stent patency. This search has led to
the use of metal expandable stents. The University of
Amsterdam investigators have compared an expandable
metal stent with apolyethylene stent (Davids et al., 1992).
The median patency for the first stent insertion was sig-
nificantly prolonged in patients with a metal stent com-
pared with the polyethylene stem, 273 days versus 126
days, respectively. The major cause of stent dysfunction
was tumor ingrowth in the metal stent group, and sludge
deposit in the polyethylene group. When stent blockage
was encountered, a polyethylene stent was inserted. Of
those patients in the metal stent group, 14 required a poly-
ethylene stent insertion, and no further occlusions were
encountered. In the group who had a polyethylene stent
initially inserted, 23 required an additional stent inserted.
Eleven ofthe 23 (48%) who had anew polyethylene stent
inserted had an additional episode of occlusion. This fact
suggests that re-occlusion is more likely to occur when
the endoscopist uses only polyethylene stents.
Since plastic stents are removable, they have been em-
ployed in the treatment ofbenign biliary strictures.A non-
randomized study by Davids (Davids et al., 1993
retrospectively compared surgical management and endo-
scopic management of benign biliary strictures.
Endoscopically placed biliary stents, which were ex-
changed every third month for a 1 year period, were com-
pared to patients who were surgically managed. Seventeen
percenthadrecurrent stricture afterundergoingendoscopic
dilatation and stenting. Anotherway that this result can be
stated is that83% oftheir strictures were patent afterbeing6 E. $. EDELL et al.
submitted to endoscopic care, while the literature fre-
quentl states that surgical management of strictures has
an 80% long-term success. The authors conclude that this
practice scheme is an acceptable way to initially manage
strictures, and that the surgical repair should be reserved
for patients who have complete transection of the duct,
failed previous surgical repair, or failed an endoscopic
treatmentprogram. Thisrecommended approach seems to
be an oversimplification of a very complex situation.
Millis (Millis et al., 1992) retrospectively analyzed 194
patients who were consecutively treated atUCLA for bile
duct strictures. Those seen from 1955 to 1979 were sep-
arately analyzed in group 1, and those seen from 1980 to
1990 were reviewed in group 2. The recurrent stricture
rate was 21 and 23% respectively. The re-operation rate
for group 1 was 21% and for group two, 6%. An expla-
nation as to why there was a striking reduction in re-op-
eration, was that 20 patients in group 2 underwent biliary
dilatation. Yet, the success of biliary dilatation varies
greatly depending upon the pathologic condition giving
rise to stricturing. Ninety-three percent of those treated
with anastomatic strictures were adequately eared for by
dilatation, whileonly50% ofpatients with aprimary stric-
ture benefited from dilatation.
Biliary endoprostheses havebeenused in elderly symp-
tomatic patients with large bile duct stones. The use of a
stent has proven to be an effective treatment for nonex-
tractable stones. An excellent article by Chung (Chung et
al., 1991) from the Prince ofWales Hospital, Hong Kong,
reviewed their experience clearing biliary ducts of large
stones. Mechanical lithotripsy was successful in 81% and
the remaining patients had their ducts cleared of calculi
by electrohydraulic lithotripsy, surgery, or stenting.
The pancreas and its aff icfions are being approached
with the insertion of straight stents. Therapeutic endo-
scopists hope that bypassing obstructive lesions will di-
minish pain and restore or preserve function. Segmental
stenotic lesions in the head region and intraductal calculi,
that are not removable, are being stented. Polyethylene
pancreatic duct stents induce changes in the pancreas of
normal dogs (Sherman et al., 1993). Similarchanges have
been observed in humans (Kozarek, 1990). It appears the
cause of this damage is related to stent occlusion or from
local ductal trauma. Due to thisknown complication, cau-
tion must be exercised in application ofpancreatic stents.
ENDOSCOPIC PLACEMENT OF
TRACHEOBRONCHIAL PROSTHESES
Many patients with malignant airway obstruction present
with disabling dyspnea that is not amenable to surgical in-
tervention. Laser resection of tumor has provided pallia-
tion in some of these patients. Unfortunately, many pa-
tients have obstruction from extrinsic compression by
tumor or enlarged lymph nodes. The development of en-
dobronchial prosthetic devices may offer some of these
patients an alternative to disabling dyspnea.
The concept of an airway prosthetic device is not new,
but unfortunately, materials and techniques for insertion
havebeenpreviously unsatisfactory. Developmentofprod-
ucts that are easer to insert and more tolerable to the pa-
tient has led to an expanded use of prosthetic devices in
the management of airway obstruction. Several types of
tracheobronchial prostheses are currently available (Clark,
1980; Cooper et al., 1981; Dumon, 1990; lnsall and
Morritt, 1991; Montgomery, 1965; Montgomery, 1968
Neville etal., 1972; Oflowski, 1987; PalieroandShepherd,
1974; Simonds et al., 1985; Uchida et al., 1988; Wallace
et al., 1986 Westaby et al., 1982; Westaby and Shepard,
1983). Threebasic types ofprosthetic devices are currently
available: 1) molded silicone prostheses, 2) expandable
metal prostheses, or 3) combinations ofmetal and silicone.
Dumon (Dumon, 1990) reported results of a silicone
stent with studs on its external surface to prevent migra-
tion. In this series, a total of 118 prostheses were inserted
in 66 patients. Immediate relief of respiratory symptoms
with significant quality of survival was achieved in all but
two cases. The prosthesis was placed in the trachea in 59
cases, the leftmainstembronchus in 34 cases, andthe fight
mainstem bronchus in 16 cases. Obstruction of the pros-
thesis by dried secretion was recorded in two patients.
Granulomas were noted in 10 cases. The authors report
migration of the prosthesis in 12 patients.
Becker (Becker, 1992) reported experience with ex-
pandable metal prostheses, mainly the Strecker stent and
the Palmaz stent. These prostheses are made of tantalum
or stainless steel compressed onto balloons and expanded
after introduction by inflation with saline solution. The
expandable metal stentsbecome epithelialized in the ideal
situation. Becker reports 36 implantations ofthe Strecker
stentwithcomplications occurring in the majority ofthese
patients. Complications included granulomatous forma-
tion with obstruction and integration into the bronchial
wall. As a result of this experience, the author does not
recommenduse ofthese prosthesis forairway obstruction.
Self-expanding metal prothesis have also been used in
the management of malignant or benign airway obstruc-
tion. Several authors have reported their experience with
these devices (Bohndorfetal., Rauberet al., 1992). Becker
reported implanation of 77 Nitinol stents. The complica-
tions appeared less than with the Strecker stents. Rousseau
reported an experience with self-expandable type pros-
thetic devices. He reported 74 stents in 62 patientsTHE USE OF PROSTHETIC STENTS 7
(Rousseau etal., 1992). Thirty-nineWallstents (trachea 14,
bronchi 25), and35 Gianturco. This series representedcon-
secutive patients with contraindications for surgery or pre-
sented with noninflammatory lesions of the trachea or
bronchus. Rousseau reported complications in 6 of 19 pa-
tients (31%) with the Gianturco self-expanding stent.
At our institution, we have had the opportunity to use
Dumon silicone stents and a specially designed Stent
Introducer System (Bryan Copr, Woburn, MA.). Forty
stents have been inserted into thirty patients. The major-
ity of these patients had malignant airway obstruction.
Other causes of airway narrowing included benign stric-
ture, Wegener’s granulomatosis, and mediastinal fibrosis.
One patient has had the prosthetic device in place formore
than 48 months. The major complication has been ob-
structionby inspisated secretions. Onepatientexperienced
stent dislodgement and one patient had a stent removed
due to intractable cough. Our experience supports the use
of silicone prostheses in selected patients with airway ob-
struction due to malignant or benign processes.
The ideal prosthetic device for tracheobronchial ob-
struction has not yetbeen witnessed. Depending on the cir-
cumstances, the silicone prosthesis oftheDumon type may
have advantages over the self-expanding metal stents.
Clearly, for the benign stricture in patients who are not sur-
gical candidates, the silicone prosthesis is the instrument of
choice. As more development occurs, the metal self-ex-
panding stentsmay findmore appropriate applications. The
combined metal silicone stents that are currently under de-
velopment may also provide a new class of stents that will
be more appropriate for patients with airway obstruction.
Summary
Endoscopic placement ofendoluminal prosthetic devices
continues to expand. Significant palliation can be accom-
plished in patients with diseases that effect not only the
vascular system, but also the genitourinary, gastrointesti-
nal, andtracheobronchial tree. Symptomsofrecurrentbul-
bar urethral strictures, benign prostatic hypertrophy, and
detrusor external sphincter dyssynergia may be managed
in some patients using these new devices. Obstruction of
the esophagus by carcinoma or obstruction of the biliary
or pancreatic ducts may also be palliated using new pros-
thetic devices. Malignancies and benign processes caus-
ing airway obstruction with resulting dyspnea may be
managedby dilatationandplacementofprosthetic devices
in the tracheobronchial tree. Although devices are avail-
able foreach ofthe above conditions, furtherdevelopment
and investigation needs to be undertaken to improve both
methods of application as well as analyze long-term re-
sults in these disorders.
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